An updated assessment of hepatitis delta prevalence among adults in Canada: A meta-analysis.
Canada
foreign‐born
hepatitis B
hepatitis D
meta‐analysis
prevalence
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
revised:
12
03
2024
received:
27
01
2024
accepted:
15
03
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
15
4
2024
Statut:
aheadofprint
Résumé
Foreign-born (FB) persons represent a large proportion of adults with chronic hepatitis B (CHB) in Canada due to higher prevalence rates in countries of birth for FB persons. Suboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of Canada HDV prevalence. We aim to provide an assessment of CHB and HDV prevalence in Canada using a comprehensive literature review and meta-analysis. A comprehensive literature review of articles reporting HBsAg seroprevalence and anti-HDV prevalence was conducted to calculate country-specific rates and pooled prevalence of CHB and HDV using meta-analyses. Country-specific CHB and HDV rate estimates were combined with number of FB persons in Canada in 2021 from Statistics Canada to estimate total numbers of FB with CHB and HDV, respectively. These estimates were combined with estimates of Canada-born persons with CHB and HDV to yield the total number of persons with CHB and HDV. In 2021, we estimated 0.550 million (M) (95% CI 0.488-0.615) persons with CHB; 0.344 M (95% CI 0.288-0.401) were FB and 0.206 M (95% CI: 0.200-0.214) were Canada-born. The weighted average HDV prevalence among FB persons in Canada was 5.19% (17,848 [95% CI 9611-26,052] persons), among whom 50% emigrated from Asia and 31% from Africa. When combined with estimates of Canada-born persons with HDV, we estimate 35,059 (95% CI: 18,744-52,083) persons with HDV in Canada. In conclusion, we estimate 0.550 M and 35,059 persons living with CHB and HDV, respectively, in Canada in 2021.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and health care burdens of Hepatitis Delta: a study of commercially insured adults in the United States. Hepatology. 2020;72:399‐411.
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228‐236.
Kamal H, Westman G, Falconer K, et al. Long‐term study of Hepatitis Delta virus infection at secondary care centers: the impact of viremia on liver‐related outcomes. Hepatology. 2020;72:1177‐1190.
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586‐592.
Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long‐term cohort study. J Hepatol. 2010;53:834‐840.
Romeo R, Del Ninno E, Rumi M, et al. A 28‐year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629‐1638.
Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749‐756.
Wong RJ, Kaufman HW, Niles JK, et al. Low performance of Hepatitis Delta virus testing among 2 National Cohorts of chronic hepatitis B patients in the United States. Am J Gastroenterol. 2022;117:2067‐2070.
Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics:utilization and testing in the United States. Virus Res. 2018;250:114‐117.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023;79:433‐460.
Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of Bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22‐32.
Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta‐analysis. Gut. 2019;68:512‐521.
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta‐analysis. J Hepatol. 2020;73:523‐532.
Shen DT, Ji DZ, Chen HY, Goyal H, Pan S, Xu HG. Hepatitis D: not a rare disease anymore: global update for 2017‐2018. Gut. 2020;69:786‐788.
Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of Hepatitis Delta virus infection. J Infect Dis. 2020;221:1677‐1687.
Wong RJ, Brosgart CL, Welch S, et al. An updated assessment of chronic hepatitis B prevalence among foreign‐born persons living in the United States. Hepatology. 2021;74:607‐626.
Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin. Hepatology. 2012;56:422‐433.
Canada S. Table 98‐10‐0349‐01 Place of Birth and Period of Immigration by Gender and Age: Canada. In. Place of Birth and Period of Immigration by Gender and Age. Canada ed. Statistics Canada; 2023.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546‐1555.
Canada S. Table 98‐10‐0347‐01 Immigrant Status and Period of Immigration by Gender and Age: Canada, Provinces and Territories. In. Immigrant Status and Period of Immigration by Gender and Age: Canada. provinces and territories ed. Statistics Canada; 2023.
Osiowy C, Swidinsky K, Haylock‐Jacobs S, et al. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Rep. 2022;4:100461.
Polaris OC. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024;80(2):232‐242.